A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages

  Buchbinder, Elizabeth I ^a   Gunturi, Anasuya ^b   Perritt, Jessica ^c   Dutcher, Janice ^d   Aung, Sandra ^c   Kaufman, Howard L ^e   Ernstoff, Marc S ^f   Miletello, Girald P ^g   Curti, Brendan D ^h   Daniels, Gregory A ⁱ   Patel, Sapna P ^j   Kirkwood, John M ^k   Hallmeyer, Sigrun ^l   Clark, Joseph I ^m   Gonzalez, Rene ⁿ   Richart, John M ^o   Lutzky, Joe ^p   Morse, Michael A ^q   Sullivan, Ryan J ^r   McDermott, David F ^s  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b LOWELL GENERAL HOSPITAL   (United States)

^c Prometheus Laboratories   (United States)

^d Cancer Research Foundation of New York   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g Hematology Oncology clinic   (United States)

^h Providence Health and Services   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^l Oncology Specialists   (United States)

^m Medicine Elizabeth Heywood   (United States)

ⁿ UNIVERSITY OF COLORADO   (United States)

^o SAINT LOUIS UNIVERSITY   (United States)

^p MOUNT SINAI MEDICAL CENTER   (United States)

^q Duke Hospital   (United States)

^r MASSACHUSETTS GENERAL HOSPITAL   (United States)

^s BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

Immune checkpoint blockade; Interleukin 2; Ipilimumab; Melanoma

Indexed keywords

ANTI PD 1; ANTINEOPLASTIC AGENT; B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; INTERLEUKIN 2; IPILIMUMAB; STEM CELL FACTOR RECEPTOR; STEROID; UNCLASSIFIED DRUG;

ACIDOSIS; ADULT; AGED; ARTICLE; AUTOIMMUNE SKIN DISEASE; CLINICAL TRIAL; COLITIS; DERMATITIS; DIARRHEA; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENE MUTATION; GUILLAIN BARRE SYNDROME; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOTENSION; ISCHEMIC COLITIS; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; MYOCARDITIS; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; TACHYCARDIA; TREATMENT RESPONSE; VITILIGO;

EID: 84997712047     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0155-8     Document Type: Article

References (13)

1. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
2. Postow MA, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-17.
3. Topalian SL, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020-30.
4. Larkin J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23-34.
5. Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109-17.
6. Atkins MB, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-16.
7. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83(4):797-805.
8. Smith FO, et al. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother. 2007;30(1):130.
9. Maker AV, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12(12):1005-16.
10. Hamid O, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204.
11. Callahan MK, Postow MA, Wolchok JD. Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol. 2013;31(2):191-9.
12. Ji RR, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61(7):1019-31.
13. Snyder A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.